Home>Topics>Companies>Biogen Idec

Biogen Idec

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Can Biogen Idec Take Wing With Tecfidera?

    Headlines

    Tue, 29 Jul 2014

    By William Meyers : Biogen Idec (NASDAQ: BIIB ) generates most of its revenue ..... approval for its hemophilia therapies. Biogen has a high trailing P/E ratio ..... expecting continued EPS growth. Biogen closed at $303.67 on July 22

  2. Biogen Idec Should Have A Strong Floor Of Support At These Levels

    Headlines

    Tue, 29 Jul 2014

    time in. I moved shares of Biogen Idec Inc . (NASDAQ: BIIB ) from my relegation league ..... portfolio after selling Hilton. Biogen Idec Inc , is a biotechnology company ..... hemophilia. On July 23, 2014, Biogen reported second quarter earnings

  3. Biogen : The Pioneer In The Hemophilia A Market

    Headlines

    Tue, 29 Jul 2014

    By Balanced Investing : Biogen Idec Inc . (NASDAQ: BIIB ), another big name in the pharmaceutical ..... for both adults and children. Biogen also received the FDA approval ..... the probability of success for Biogen to make money out of its discovery

  4. Cramer's Mad Money: The 4 Horsemen Trample Big Pharma (7/23/14)

    Headlines

    Thu, 24 Jul 2014

    Regeneron (NASDAQ: REGN ), Gilead (NASDAQ: GILD ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), GlaxoSmithKline ..... Horsemen": Regeneron ( REGN ), Gilead ( GILD ), Biogen Idec ( BIIB ) and Celgene ( CELG ). Sales of these four surpass

  5. UPDATE 4- Biogen revenue trounces forecast as MS drug sales surge

    Headlines

    Wed, 23 Jul 2014

    July 23 (Reuters) - Biogen Idec Inc reported blowout quarterly results and raised its full-year forecast on Wednesday on surging sales of its new Tecfidera oral treatment for multiple sclerosis,...

  6. Biogen's Results Cure Some Pain

    Headlines

    Wed, 23 Jul 2014

    comments sent the Biotech Index and bellwethers like Biogen (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ), and Gilead (NASDAQ ..... biotech names, not the large cap names. Clearly, Biogen Idec 's "valuation" is less of a concern given the

  7. Biogen Idec's ( BIIB ) CEO George Scangos on Q2 2014 Results - Earnings Call Transcript

    Headlines

    Wed, 23 Jul 2014

    Biogen Idec Inc . (NASDAQ: BIIB ) Q2 2014 Earnings Conference Call July 23, 2014 09:00 ET Executives ..... today. At this time, I would like to welcome everyone to the Biogen Idec Q2 2014 Earnings Conference Call. All lines have been placed

  8. Biogen Idec Beats And Raises: Reassessing Its Prospects

    Headlines

    Wed, 23 Jul 2014

    lines and pipeline of Biogen Idec (NASDAQ: BIIB ). This is a company ..... too low here and that BIIB is probably headed for ..... ground. Introduction : Biogen Idec reported blowout numbers today: Biogen Idec Inc . today reported second

  9. EC clears Plegridy

    Headlines

    Wed, 23 Jul 2014

    The European Commission approves Biogen Idec 's ( BIIB +11.2% ) Plegridy ( peginterferon beta-1a ) as a treatment ..... subcutaneous injection using a prefilled syringe. Plegridy is Biogen 's fifth product offering for MS. Post your comment!

  10. BRIEF- Biogen says tax inversions are not an adequate rationale for mergers

    Headlines

    Wed, 23 Jul 2014

    July 23 (Reuters) - Biogen Idec Inc : * Says in an investor conference call that company does not think tax inversions are an adequate rationale for business

« Prev12345Next »
Content Partners